Second and third TNF inhibitors in European patients with axial spondyloarthritis

• Autor(a) principal: Linde, Louise
• Data de Publicação: 2023
• Outros Autores: Ørnbjerg, Lykke Midtbøll, Brahe, Cecilie Heegaard, Wallman, Johan Karlsson, Di Giuseppe, Daniela, Závada, Jakub, Castrejon, Isabel, Díaz-Gonzalez, Federico, Rotar, Ziga, Tomšič, Matija, Glintborg, Bente, Gudbjornsson, Bjorn, Geirsson, Arni Jon, Michelsen, Brigitte, Kristianslund, Eirik Klami, Santos, Maria José, Barcelos, Anabela, Nordström, Dan, Eklund, Kari K, Ciurea, Adrian, Nissen, Michael, Akar, Servet, Hyldstrup, Lise Hejl, Krogh, Niels Steen, Hetland, Merete Lund, Østergaard, Mikkel
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10362/160037
• topic: Axial spondyloarthritis; adverse events; effectiveness; ack of efficacy; switching TNF-inhibitors

OBJECTIVE: To investigate real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and the association with 1) treatment line (second and third TNFi-series) and 2) reason for withdrawal from the preceding TNFi (lack of efficacy (LOE) versus adverse events (AE)). METHODS: Prospectively collected routine care data from 12 European registries were pooled. Rates for 12-month drug retention and 6-month remission (Ankylosing Spondylitis Disease Activity Score C-reactive protein inactive disease (ASDAS-ID)) were assessed in second and third TNFi-series and stratified by withdrawal reason. RESULTS: We included 8254 s and 2939 third TNFi-series; 12-month drug retention rates were similar (71%). Six-month ASDAS-ID rates were higher for the second (23%) than third TNFi (16%). Twelve-month drug retention rates for patients withdrawing from the preceding TNFi due to AE versus LOE were similar for the second (68% and 67%) and third TNFi (both 68%), while for the second TNFi, rates were lower in primary than secondary non-responders (LOE < 26 versus ≥26 weeks) (58% versus 71%, p< 0.001). Six-month ASDAS-ID rates for the second TNFi were higher if the withdrawal reason was AE (27%) versus LOE (17%), p< 0.001, while similar for the third TNFi (19% versus 13%, p= 0.20). CONCLUSION: A similar proportion of axSpA patients remained on a second and third TNFi after one year, but with low remission rates for the third TNFi. Remission rates on the second TNFi (but not the third) were higher if the withdrawal reason from the preceding TNFi was AE versus LOE.